Ro5-3335
Based on 13 publication(s) in Google Scholar
Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.35%
- CAS No.: 30195-30-3
- 화학식: C13H10ClN3O
- 분자량:259.69
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Blood Cancer Compound Library
HY-L079
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Ro5-3335
More- Nat Immunol. 2023 Dec;24(12):2042-2052. [Abstract]
- Nat Commun. 2024 Sep 16;15(1):8114. [Abstract]
- Theranostics. 2024 Jul 8;14(11):4256-4277. [Abstract]
- Arch Pharm Res. 2025 Dec;48(11-12):1399-1419. [Abstract]
- Free Radic Biol Med. 2024 Sep:222:288-303. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116495. [Abstract]
- Biochem Pharmacol. 2023 Nov:217:115808. [Abstract]
- Brain Res Bull. 2026 Feb:235:111746. [Abstract]
- Adv Ophthalmol Pract Res. 2025 Nov 21.
- J Immunol. 2025 Aug 7:vkaf170. [Abstract]
- J Dent Sci. 2023 Oct;18(4):1553-1560. [Abstract]
- bioRxiv. 2026 May 15:2026.05.14.725187. [Abstract]
- bioRxiv. 2026 May 22:2026.05.20.726667. [Abstract]
Customer Validation & Images
-
WB
-
RT-PCR
-
Histological Imaging/Staining
-
IF
-
Cell Proliferation/Viability Assay
Biological Activity
|
RUNX1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H9 | IC50 |
0.6 μM
Compound: 1
|
Inhibition of HIV replication in H9 cells.
Inhibition of HIV replication in H9 cells.
|
[PMID: 7650672] |
| H9 | IC50 |
0.6 μM
Compound: 1
|
Inhibition of HIV-1 replication in H9 cells infected with three different concentrations of HIV IIIB strain
Inhibition of HIV-1 replication in H9 cells infected with three different concentrations of HIV IIIB strain
|
[PMID: 8410982] |
| SW480 | IC50 |
4 μM
Compound: 1
|
The compound was tested for inhibition of HIV-1 replication in SW480 cells using HIV tat assay
The compound was tested for inhibition of HIV-1 replication in SW480 cells using HIV tat assay
|
[PMID: 7650672] |
Ro5-3335 has antiproliferative activity against human CBF leukemia cell lines, with IC50s of 1.1 μM, 21.7 μM and 17.3 μM for ME-1, Kasumi-1 and REH, respectively[1].
Ro5-3335 inhibits definitive hematopoiesis in zebrafish embryos[1].
Ro5-3335 does not completely break apart RUNX1-CBFβ interaction, but changes the conformation of their complex or increases the distance between RUNX1 and CBFβ in the complex[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ro5-3335 rescues preleukemic phenotype in a RUNX1-ETO transgenic zebrafish[1].
Ro5-3335 (300 mg/kg/d; p.o; for 30 days) reduces leukemia burden in a mouse CBFB-MYH11 leukemia model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (leukemic model)[1]
-
Dosage:300 mg/kg
-
Administration:Oral administration; daily; for 30 days
-
Result:Reduced the number of c-kit+ cells in the transplanted mice and leukemic cell infiltration in the livers, bone marrow and spleen.
Chemical Information
-
CAS No. 30195-30-3
-
Appearance Solid
-
분자량 259.69
-
화학식 C13H10ClN3O
-
Color Off-white to light yellow
-
SMILES
O=C1NC2=CC=C(Cl)C=C2C(C3=CC=CN3)=NC1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1. [Abstract]2023 Dec;24(12):2042-2052. PMID: 37919525
Ro5-3335 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Dec;24(12):2042-2052. [Abstract]
MEPs were isolated from healthy C57BL/6J mice and treated with Kyn or Kyn combined with the RUNX1 inhibitor Ro5-3335 (2 μM) in collagen medium for 7 d, and a c.f.u. analysis was performed.
-
Nat Commun
2024 Sep 16;15(1):8114. PMID: 39284834
Ro5-3335 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 16;15(1):8114. [Abstract]
Western blotting for scWAT RUNX1 protein in WT (dark gray) and Tg6 (red) mice treated with RUNX1 inhibitor Ro5-3335 (5 mg/kg; s.c.; every other day for six times) or DMSO control. Ro5-3335 attenuated the increase in RUNX1 protein in scWAT of Tg6-mice compared with WT-mice.
Ro5-3335 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Sep 16;15(1):8114. [Abstract]
Lipid metabolism gene expression (qPCR) in scWAT of WT and Tg6-mice treated with RUNX1 inhibitor Ro5-3335 (5 mg/kg; s.c.; every other day for six times). Ro5-3335 administration attenuated the changes observed in Tg6-mice associated with high EPO on expression of lipid metabolismgenes.
-
Theranostics
Methyl-CpG-binding 2 K271 lactylation-mediated M2 macrophage polarization inhibits atherosclerosis. [Abstract]2024 Jul 8;14(11):4256-4277. PMID: 39113793
Ro5-3335 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jul 8;14(11):4256-4277. [Abstract]
ApoE-/- mice receiving HFD for 8 weeks were treated with Ro5-3335 (25 mg/kg; i.p.; twice a week for 4 weeks; DMSO) or DMSO starting at week 8. Representative images and quantification of atherosclerotic area in cross-sections of aortic root of ApoE-/- mice treated with Ro5-3335 and DMSO by HE, Oil Red O and Masson staining.
Ro5-3335 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jul 8;14(11):4256-4277. [Abstract]
Representative images of immunofluorescence co-staining for RUNX1 together with macrophage maker F4/80 and M2 macrophage marker CD206 in aortic root plaques from ApoE-/- mice treated with Ro5-3335 (25 mg/kg; i.p.; twice a week for 4 weeks; DMSO) and DMSO, with quantification of immunofluorescence intensity.
-
Arch Pharm Res
Salvianolic acid A enhances Treg accumulation via the RUNX1/CBFβ/FOXP3 axis as a neuroprotective immunomodulator in ischemic stroke. [Abstract]2025 Dec;48(11-12):1399-1419. PMID: 41201767 -
Free Radic Biol Med
Cannabidiol mitigates radiation-induced intestine ferroptosis via facilitating the heterodimerization of RUNX3 with CBFβ thereby promoting transactivation of GPX4. [Abstract]2024 Sep:222:288-303. PMID: 38830513 -
Cell Rep
CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability. [Abstract]2025 Nov 25;44(11):116495. PMID: 41176765 -
Biochem Pharmacol
Scutellarin suppresses the metastasis of triple-negative breast cancer via targeting TNFα/TNFR2-RUNX1-triggered G-CSF expression in endothelial cells. [Abstract]2023 Nov:217:115808. PMID: 37716622 -
Brain Res Bull
Dendrobine attenuates postoperative cognitive dysfunction by inhibiting Runx1-mediated NF-κB signaling pathway. [Abstract]2026 Feb:235:111746. PMID: 41616945 -
-
J Immunol
TLR7-mediated immune response of renal myeloid-derived suppressor cells via RUNX1-KLF4 in systemic candidiasis. [Abstract]2025 Aug 7:vkaf170. PMID: 40795213 -
J Dent Sci
Kartogenin potentially protects temporomandibular joints from collagenase-induced osteoarthritis via core binding factor β and runt-related transcription factor 1 binding - A rat model study. [Abstract]2023 Oct;18(4):1553-1560. PMID: 37799879 -
bioRxiv
Impaired SOX17 Expression Causes Endothelial Dysfunction and Pulmonary Arterial Hypertension by Insufficient Suppression of RUNX1. [Abstract]2026 May 15:2026.05.14.725187. PMID: 42182299 -
bioRxiv
Cholangiocyte RUNX1 Orchestrates Fibrogenic and Inflammatory Signaling to Drive Biliary Fibrosis. [Abstract]2026 May 22:2026.05.20.726667. PMID: 42239059
용액&용해도
DMSO : 100 mg/mL (385.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.63 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8507 mL | 19.2537 mL | 38.5075 mL | 96.2686 mL |
| 5 mM | 0.7701 mL | 3.8507 mL | 7.7015 mL | 19.2537 mL | |
| 10 mM | 0.3851 mL | 1.9254 mL | 3.8507 mL | 9.6269 mL | |
| 15 mM | 0.2567 mL | 1.2836 mL | 2.5672 mL | 6.4179 mL | |
| 20 mM | 0.1925 mL | 0.9627 mL | 1.9254 mL | 4.8134 mL | |
| 25 mM | 0.1540 mL | 0.7701 mL | 1.5403 mL | 3.8507 mL | |
| 30 mM | 0.1284 mL | 0.6418 mL | 1.2836 mL | 3.2090 mL | |
| 40 mM | 0.0963 mL | 0.4813 mL | 0.9627 mL | 2.4067 mL | |
| 50 mM | 0.0770 mL | 0.3851 mL | 0.7701 mL | 1.9254 mL | |
| 60 mM | 0.0642 mL | 0.3209 mL | 0.6418 mL | 1.6045 mL | |
| 80 mM | 0.0481 mL | 0.2407 mL | 0.4813 mL | 1.2034 mL | |
| 100 mM | 0.0385 mL | 0.1925 mL | 0.3851 mL | 0.9627 mL |
Ro5-3335 Related Classifications
HY-108470 Related Classifications
Powered by Bioz